Physician profile
Andrew Oh
NPI 1285637686
$2,544.44
in general payments reported to CMS, 2019-2025
26 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $755 · 2021: $395 · 2022: $218 · 2023: $239 · 2024: $84.38 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $721.76 | 2019-2022 | |
| Renovia INC | $567.22 | 2019-2020 | |
| Hologic Sales and Service, LLC | $229.29 | 2021-2025 | Omni Hysteroscope, Novasure, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $172.03 | 2019-2025 | |
| Astellas Pharma US INC | $168.11 | 2022-2025 | Veozah |
| Amag Pharmaceuticals, INC. | $117.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $113.99 | 2019 | |
| Channel Medsystems, INC. | $95.77 | 2023 | |
| Pfizer INC. | $65.11 | 2022 | |
| Axonics, INC. | $43.11 | 2023 | Axonics |
| Myovant Sciences INC. | $32.14 | 2022 | |
| Avion Pharmaceuticals | $26.62 | 2021 | |
| Therapeuticsmd, INC. | $24.55 | 2020-2021 | |
| Daiichi Sankyo INC. | $19.43 | 2020 | |
| Allergan, INC. | $19.14 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $17.57 | 2019 | |
| Aspira Women'S Health INC | $17.39 | 2021 | |
| Mayne Pharma Commercial LLC | $16.71 | 2025 | |
| Coopersurgical, INC. | $14.83 | 2024 | Paragard T 380a |
| Sage Therapeutics, LLC | $14.64 | 2024 | |
| Vertical Pharmaceuticals, LLC | $14.17 | 2019 | |
| Olympus America INC. | $12.74 | 2019 | |
| Organon LLC | $11.35 | 2025 | Nexplanon |
| Meditrina | $9.29 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.